Oslo, Norway, 20 May 2026: Reference is made to the Annual General Meeting (the "AGM") of Oncoinvent ASA (the "Company") earlier today where the nomination committee's proposal for remuneration for the members of the Board was approved.

The AGM approved the following share option remuneration to the Board.

• Chair of the Board: 1,708 share options
• Board members: 854 share options

Share options normally vest over a four-year period as follows: no options shall vest during the first 12 months following the date of the grant, 13/48 of the options shall vest in the 13th month, the remaining options shall thereafter vest in equal monthly instalments of 1/48. Options expire seven years after the grant date.

The exercise price for this grant is NOK 46,5195 per option equal to the volume weighted average share price (VWAP) the last day before the grant.  

The following members of the Board of Oncoinvent ASA has received share options grants, according to the terms described above:

• Gillies O'Bryan-Tear (Chairperson of the Board) has been granted 1,708 share options. Following the grant, he holds 26,369 shares and 5,245 share options in Oncoinvent ASA.
• Kari Grønås (Board member) has been granted 854 share options. Following the grant, she holds 902 shares and 2,506 share options in Oncoinvent ASA.
• Hilde Steineger (Board member) has been granted 854 share options. Following the grant, she holds no shares and 2,506 share options in Oncoinvent ASA.
• Orlando Oliveira (Board member) has been granted 854 share options. Following the grant, he holds no shares and 2,506 share options in Oncoinvent ASA.
• Johan Häggblad (Board member) has been granted 854 share options. Following the grant, he holds no shares and 1,804 share options in Oncoinvent ASA.
• Olav Hellebø (Board member) has been granted 854 share options. In addition, he receives an option grant equivalent to the option allocation to Board members of Oncoinvent ASA approved by the 2025 AGM, adjusted for actual time served, amounting to a total of 554 share options. These options are granted at an exercise price equal to the volume weighted average share price (VWAP) on the last trading day before the merger; both the number of share options and exercise price have been adjusted for the previous reverse share split and reduction of nominal value. Following these grants, he holds 2,000 shares and 1,408 share options in Oncoinvent ASA.

PDMR notifications 20 May 2026 - grant of board options.pdf

This information is subject to the disclosure requirements pursuant to article 19 of the regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the Norwegian Securities Trading Act.